Revolution Medicines officer sells 4,175 shares

Revolution Medicines, Inc. executive Stephen Michael Kelsey reported an open-market sale of 4,175 shares of common stock on June 16, 2026 at a weighted average price of $156.1192 per share.

Rhea-AI Filing Summary

Revolution Medicines, Inc. executive Stephen Michael Kelsey reported an open-market sale of 4,175 shares of common stock on June 16, 2026 at a weighted average price of $156.1192 per share. The footnotes state this transaction was executed under a pre-arranged Rule 10b5-1 instruction letter intended to satisfy tax withholding obligations related to vested restricted stock units. After the sale, Kelsey directly owned 291,876 shares, which the disclosure notes includes 76,251 RSUs and 653 shares acquired through the company’s Employee Stock Purchase Plan.

Insider Trade Summary 10b5-1

Net Seller: 4,175 shares

Net Sell 1 txn

Insider Kelsey Stephen Michael

Role See Remarks

Sold 4,175 shs ($652K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,175	$156.1192	$652K

Holdings After Transaction: Common Stock — 291,876 shares (Direct)

Footnotes (4)

1. F1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.
2. F2. This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8250. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. F3. Includes 76,251 RSUs.
4. F4. Includes 653 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.

Key Figures

Shares sold: 4,175 shares Weighted average sale price: $156.1192 per share Shares owned after transaction: 291,876 shares +2 more

5 metrics

Shares sold 4,175 shares Open-market sale on June 16, 2026

Weighted average sale price $156.1192 per share Common stock sale

Shares owned after transaction 291,876 shares Direct holdings following sale

Included RSUs 76,251 RSUs Part of post-transaction holdings

ESPP shares included 653 shares Acquired under Employee Stock Purchase Plan on May 31, 2026

Key Terms

Rule 10b5-1 instruction letter, restricted stock units ("RSUs"), Employee Stock Purchase Plan

3 terms

Rule 10b5-1 instruction letter regulatory

"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023"

restricted stock units ("RSUs") financial

"to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs")"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Employee Stock Purchase Plan financial

"Includes 653 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

FAQ

What insider transaction did RVMD executive Stephen Michael Kelsey report?

Stephen Michael Kelsey reported selling 4,175 shares of Revolution Medicines common stock. The shares were sold on June 16, 2026 in an open-market transaction at a weighted average price of $156.1192 per share, according to the Form 4 disclosure.

Was the June 16, 2026 RVMD insider sale by Kelsey pre-planned?

Yes. The filing states the sale was made under a Rule 10b5-1 instruction letter adopted May 31, 2023. Such plans pre-schedule trades, indicating this transaction followed a pre-arranged program rather than a discretionary market-timing decision.

Why did RVMD insider Stephen Michael Kelsey sell 4,175 shares?

The footnotes explain the transaction was designed to satisfy Kelsey’s tax withholding obligation related to vesting restricted stock units. This frames the sale as a tax-related liquidity event rather than a standalone change in long-term equity exposure.

How many Revolution Medicines shares does Kelsey hold after this Form 4 sale?

After the sale, Kelsey directly owned 291,876 shares of Revolution Medicines common stock. The reported total includes 76,251 restricted stock units and 653 shares acquired through the company’s Employee Stock Purchase Plan, as detailed in the filing footnotes.

At what price did RVMD insider Kelsey sell his shares on June 16, 2026?

The Form 4 reports a weighted average sale price of $156.1192 per share. Footnotes note multiple trades executed between $156.1105 and $156.8250, with the average price figure summarizing those individual executions.

What equity awards are included in Kelsey’s reported RVMD holdings?

Kelsey’s reported 291,876 shares include 76,251 restricted stock units and 653 shares from the Employee Stock Purchase Plan. This mix highlights both time-based equity awards and employee share purchases within his overall position in Revolution Medicines.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelsey Stephen Michael

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2026		S(1)		4,175	D	$156.1192(2)	291,876(3)(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

2. This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8250. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. Includes 76,251 RSUs.

4. Includes 653 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.

Remarks:

President, Research and Development

	/s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)